Download Image
    
Share
  
Post
c19early.org
Artemisinin for COVID-19
3 studies with 217 patients
Serious outcome risk
Artemisinin
Control
Significantly lower risk for recovery.
One study shows significant benefit.
COVID-19 Artemisinin studies · October 2026
Artemisinin was adopted in 13 countries. Recent:
Strub-Wourgaft
Chiririwa
Shaer.
Covid Analysis Artemisinin reduces COVID-19 risk: real-time meta-analysis of 3 studies
Significantly lower risk is seen for recovery. One study shows significant benefit. Meta-analysis using the most serious outcome reported shows 34% [11‑51%] lower risk. Results are similar for peer-reviewed studies and better f..
Apr 28
 Chiririwa, H., Pharmaceuticals, doi:10.3390/ph19060869 Selected Cannabinoids, Cannabimimetic Agents and Artemisia Combinations as Theoretical Adjunct Strategies Against COVID-19
Review of cannabinoids, cannabimimetic compounds, and Artemisia species as potential therapeutic agents for COVID-19.
Dec 17
2025
 Shaer et al., Pharmaceuticals, doi:10.3390/ph18121904 Potential of Artemisia annua Bioactives as Antiviral Agents Against SARS-CoV-2 and Other Health Complications
Review of the potential of Artemisia annua bioactive compounds as antiviral agents against SARS-CoV-2. Authors highlight that artemisinin and its derivatives demonstrate strong binding to the Lys353 and Lys31 hotspots of the SARS-CoV-2 sp..
Jul 31
2025
 Abayomi Banjo et al., Rwanda Journal of Medicine and Health Sciences, doi:10.4314/rjmhs.v8i2.2 Tumor Necrosis Factor-Alpha (TNF- α) and Antiviral Activities of Artemisia SPP. Extracts on SARS-COV2
In vitro and cross-sectional study showing that Artemisia afra and Artemisia annua extracts inhibit TNF-α levels in SARS-CoV-2 infected patients by approximately 50-70% in severe cases. Authors analyzed the phytochemical composition of et..
Nov 15
2024
 Navacchia et al., Molecules, doi:10.3390/molecules29225403 Insights into SARS-CoV-2: Small-Molecule Hybrids for COVID-19 Treatment
Review of recent advances in small-molecule hybrid compounds as potential antiviral agents against SARS-CoV-2. Authors provide an overview of hybrids, which are formed by covalently linking two or more pharmacophores, as a promising appro..
Oct 26
2024
 Bagheri-Far et al., Molecular Biology Research Communications, doi:10.22099/mbrc.2024.50245.2001 Non-spike protein inhibition of SARS-CoV-2 by natural products through the key mediator protein ORF8
In silico study showing that ivermectin, artemisinin, and DEG-168 may inhibit SARS-CoV-2 by targeting the ORF8 protein's binding sites. Ivermectin showed the highest binding affinity. Authors identified two key binding regions on ORF8 - a..
May 18
2024
 Fowler et al., NCT04330690 A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Estimated 966 patient artemisinin late treatment RCT with results not reported over 2 years after estimated completion.
May 15
2024
 Irfan et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09387-w Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study
In silico study showing that artemisinin and artesunate from Artemisia annua bind to the SARS-CoV-2 main protease (Mpro), with artesunate exhibiting a binding score of -7.5 kcal/mol. Authors screened 25 phytoconstituents, identifying arte..
Mar 28
2024
 Strub-Wourgaft et al., ANTICOV An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19
92% lower progression (p=0.38) and 94% lower hospitalization (p=0.14). RCT 1,942 patients testing HCQ, lopinavir/ritonavir, nitazoxanide/ciclesonide, ivermectin/ASAQ, and fluoxetine/budesonide compared wirth paracetamol. Control patients were assigned to paracetamol as needed for fever or pain, however treat..
Jan 2
2024
 El-Megharbel et al., PeerJ, doi:10.7717/peerj.15638 Chemical and spectroscopic characterization of (Artemisinin/Quercetin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats
In vitro and animal study showing that a novel artemisinin/quercetin/zinc (Art/Q/Zn) complex exhibits potent anti-SARS-CoV-2 activity (IC50 = 10.14 μg/ml) without cytotoxicity (CC50 = 208.5 μg/ml). The complex alleviates acrylamide-induce..
Dec 1
2022
 Gyanwali et al., NCT05273242 WHO Solidarity Trial Plus: An International Randomised Trial of Additional Treatments for COVID-19 in Hospitalised Patients Who Are All Receiving the Local Standard of Care in Nepal
Estimated 400 patient artemisinin late treatment RCT with results not reported over 3 years after estimated completion.
Nov 1
2022
 Chandiwana et al., eBioMedicine, doi:10.1016/j.ebiom.2022.104322 Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
29% lower progression (p=0.66), 27% faster recovery (p=0.1), and 1% worse viral clearance (p=0.76). High COI low-risk patient RCT in South Africa, showing no significant differences with artesunate-amodiaquine or pyronaridine-artesunate.
Feb 7
2022
 Farmanpour-Kalalagh et al., Frontiers in Plant Science, doi:10.3389/fpls.2022.780257 Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand
Review of artemisinin and related compounds (artemisinins) for their potential in combating viral infections, inflammation, and cancers, with a special focus on SARS-CoV-2/COVID-19. Authors explain that artemisinin, a sesquiterpene lacton..
Feb 7
2022
 Schultz et al., Nature, doi:10.1038/s41586-022-04482-x Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
In vitro and mouse study showing synergistic antiviral effects when combining pyrimidine biosynthesis inhibitors with antiviral nucleoside analogues against SARS-CoV-2. Authors screened 18 thousand drugs and validated 122 with antiviral a..
Mar 19
2021
 Uckun et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.649532 Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug
Review of artemisinin, an anti-malaria phytomedicine with anti-inflammatory properties, as a potential COVID-19 drug. Authors explain that artemisinin, discovered by Nobel laureate Tu Youyu, shows broad-spectrum antiviral activity and spe..
Feb 1
2021
 Trieu et al., medRxiv, doi:10.1101/2021.01.24.21250418 Targeting TGF-β pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19
52% improved recovery (p=0.08). RCT 60 mild-moderate COVID-19 patients showing faster recovery with artemisinin.
Apr 28
2020
 Lin et al., China Critical Care Medicine, doi:10.3760/cma.j.cn121430-20200312-00412 Clinical study of artesunate in the treatment of coronavirus disease 2019
31% faster recovery (p=0.02), 8% shorter hospitalization (p=0.22), and 29% faster viral clearance (p=0.05). Prospective study of 43 hospitalized COVID-19 patients in China showing faster symptom improvement and shorter hospitalization with artesunate. Artesunate 60 mg twice daily for 10 days.
Apr 24
2020
 Sekiou et al., ChemRxiv, doi:10.26434/chemrxiv.12181404.v1 In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2
In silico study of natural compounds identifying quercetin, curcumin, hispidulin, cirsimaritin, sulfasalazine, and artemisin as potential compounds that inhibit SARS-CoV-2.